A Randomized, Double-Blinded, Placebo-Controlled Trial to Determine The Safety and Efficacy of CYR-064
Latest Information Update: 06 May 2024
At a glance
- Drugs Theophylline (Primary)
- Indications Anosmia; Olfaction disorders; Taste disorders
- Focus Adverse reactions
- Acronyms FLAVOR trial
- Sponsors Cyrano Therapeutics
- 16 Jan 2024 According to a Cyrano Therapeutics media release, the company has secured a $9.0 million Series B financing from which proceeds will be used to fund this trial through read out.
- 12 Oct 2023 According to a Cyrano Therapeutics media release, status changed from not yet recruiting to recruiting.
- 12 Oct 2023 According to a Cyrano Therapeutics media release, this multi-institutional prospective study is being conducted at fifteen clinical sites in the United States.